15 16 Most diagnostic tests for tuberculosis (TB) rely on sputum samples, which are difficult to obtain and have 17 low sensitivity in immunocompromised patients, patients with disseminated TB, and children, delaying 18 treatment initiation. The World Health Organization (WHO) calls for the development of a rapid, 19 biomarker-based, non-sputum test capable of detecting all forms of TB at the point-of-care to enable 20 immediate treatment initiation. Lipoarabinomannan (LAM) is the only WHO-endorsed TB biomarker 21 which can be detected in urine, an easily collected sample. This review discusses the characteristics of 22 LAM as a biomarker, describes the performance of first-generation urine LAM tests and reasons for slow 23 uptake, and presents considerations for developing the next-generation of more sensitive and impactful 24 tests. Next-generation urine LAM tests have the potential to reach adult and pediatric patients 25 regardless of HIV status or site of infection and facilitate global TB control. Implementation and scale-up 26 of existing LAM tests and development of next-generation assays should be prioritized. 27 28 Word count (200 max): 156 29 30 Key Words: Tuberculosis (TB), diagnostics, Lipoarabinomannan (LAM), urinary tests 31 32 33 34 Funding: This research received no external funding.
Introduction 38
Tuberculosis (TB) has infected one-quarter of the world's population and is the leading infectious cause 39 of mortality worldwide [1] . Ten million people develop active TB each year, one million of whom are 40 children [1] . An estimated 36% of new TB cases remain undiagnosed or unreported, partly due to the 41 major limitations of current diagnostic tools [1] . Most conventional diagnostic tests for microbiological mycobacteria (Mtb, M. leprae, M. avium and M. kansasii) is modified with one to three α(1→2)-linked 82 mannopyranose (Manp) units (ManLAM) . Mtb ManLAM can contain an additional cap modification, 5-83 deoxy-5-methylthio-xylofuranose (MTX), attached to the terminal Manp [14, 15] . 84 85
As replicating Mtb degrades, LAM circulating in the blood is filtered across the glomerular basement 86 membrane of the kidneys into urine (Figure 1) . The presence of LAM in urine can also be a result of renal 87
Mtb infection, as has been shown in autopsy studies [16] . 88 89
There is no consensus about LAM concentration ranges in different sample matrices due to the lack of 90 standardized LAM control materials and sample panels and the absence of reference assays. Four recent 91 studies used the same purified LAM material for calibration and similar antibody reagents for 92 immunoassay-based LAM detection (though different detection platforms) and reported LAM 93 concentrations in sputum [17] , blood [18, 19] , and urine [20] in subjects with active pulmonary TB, 94
allowing for a rough comparison of LAM concentration ranges. For sputum, Kawasaki and colleagues 95 showed that an immunoassay with a cut-off of 15 pg/ml detected all smear-positive and 50% of smear-96 negative TB patients [17] and sputum LAM concentrations ranged from 15.4 pg/ml to 1,869,000 pg/ml 97 (median 5512 pg/ml). LAM concentration in sputum was linearly correlated to colony forming units (CFU) 98
with 1 pg/ml of LAM correlating to 8 CFU/ml, suggesting that one Mtb bacterium contains approximately 99 125 fg of LAM [17] . Brock et al [19] developed a sensitive serum assay using Single Molecule Array 100 (Simoa); using a cutoff of 2.3 pg/mL the assay sensitivity in smear-positive TB patients was 40%, and 60% 101 in HIV-positive/smear-positive TB patients at 100% specificity. Serum LAM concentrations in this study 102
were highest in HIV-positive/smear-positive patients (median 3.97 pg/mL). Broger and colleagues 103 developed sensitive immunoassays and compared serum LAM to urine LAM concentrations in matched 104 samples from smear-positive TB patients [18, 20] . The serum assay detected LAM in 55% of smear-105 positive patients with concentrations of 6 pg/ml to 70,000 pg/ml but 45% of patients were below the 106 cut-off of 6 pg/ml, suggesting a median concentration in serum of roughly 10 pg/ml. In the same sample 107 set, the urinary LAM assay with a cut-off of 11 pg/ml showed that nearly all patients (93%) had 108 concentrations in the range of 12 pg/ml to 90,000 pg/ml (median 111 pg/ml anemic patients, by -9.0% (95% CI: -16.6% to -1.3%; p=0.021), and those with clinically suspected TB, by 166 -5.7% (95% CI: -10.9% to -0.5%; p=0.033) [30] . The authors concluded that urine LAM could reduce 167 mortality in these high-risk groups and argued for a use for screening in all HIV-positive inpatients. A 168 third RCT (TB Fast Track, Grant et al.) randomly assigned HIV-positive adults (aged ≥18 years) with CD4 169 counts of ≤150 cells/μL, who had not had antiretroviral therapy (ART) in the past 6 months 1:1 to either 170 routine care or the interventional arm [31] . In the interventional arm study nurses assessed participants 171 on the basis of tuberculosis symptoms, body-mass index, point-of-care haemoglobin concentrations, and 172
urine AlereLAM results. Participants in the interventional arm classified as having high probability of 173 tuberculosis were recommended to start tuberculosis treatment immediately followed by ART two 174 weeks later; participants classified as medium probability were recommended to have symptom-guided 175 investigation; and participants classified as low probability were recommended to start ART 176
immediately. Although the intervention substantially increased coverage of tuberculosis treatment in 177 this high-risk population it did not reduce mortality and the authors proposed to prioritize the AlereLAM test usage within its algorithms. The uptake has been further boosted by the involvement of 195 patient advocacy groups such as TAG and others [37, 38] . methods and reached 65.5% sensitivity at 84% specificity in a study of 45 HIV-positive and 74 HIV-218 negative patients [45] . While all these assays showed promising sensitivities (65 to 95%) they all have 219 specificities below 85% and would not meet the minimal target of ≥98% of the biomarker TPP (Table 1) . 220 221
In contrast, Sigal et al. developed a sensitive research assay that approaches the performance targets of 222 the biomarker TPP. The assay is targeting the MTX-LAM epitope (Figure 1 ) in urine and reached 93% 223 sensitivity and 97% specificity in a case-control study with 40 TB-positive and 35 HIV-negative patients 224
with a cut-off of 11 pg/ml [46] . The study underlines the importance of using reagents that target Mtb-225 charateristic LAM epitopes to maintain a high diagnostic specificity at very low assay cut-offs. Fujifilm, Tokyo, Japan, Figure 1 ), which is a well-advanced next-generation LAM test (CE-marked)[47] 229
( Table 1) . The assay combines a pair of high-affinity monoclonal antibodies directed towards the largely 230
Mtb-specific MTX-LAM epitopes and a silver-based amplification step that increases the visibility of test 231
and control lines of a lateral-flow assay to reach a cut-off around 30 this, a combination of a microbiological reference standard (MRS) and a composite reference standard 258 (CRS) or latent class analysis should be considered [56] . The MRS should combine results from several 259 pulmonary samples (at least two, and including sputum induction if needed) as well as extrapulmonary 260 samples (such as urine, blood or others as indicated by the patient's presentation) to perform multiple 261
Xpert tests and mycobacterial cultures to define 'Definite TB'. The CRS combines this with chest X-ray, 262
clinical suspicion and treatment initiation to define 'Possible TB' [56] . A patient follow-up period of 8 to 263 12 weeks or longer, including observation of clinical improvement in the absence of treatment, is critical 264
to establish a 'Non-TB' diagnosis [56] . Cross-reactivity to other pathogens and colonizing organisms also 265 needs to be critically evaluated in both analytical and clinical studies. Importantly, LAM assays can 266 diagnose TB in patients unable to produce sputum, therefore the analysis of diagnostic yield is important 267
and patients unable to produce sputum should not be excluded as this group might benefit most from 268 urinary LAM testing. Also, evaluation of incremental diagnostic yield of urinary LAM diagnostics in 269 combination with sputum-based diagnostics should be considered. Other common considerations are 270 user subjectivity in test interpretation if the readout is visual, as is the case for AlereLAM and FujiLAM, 271
and ensuring generalizability across settings of implementation. 272 273
Future directions and potential impact 274
The impact of any large-scale rollout of a next-generation LAM test will ultimately be measured by 275 reduction in disease mortality and incidence at the population level. In high-burden settings, this will 276 depend significantly on achieving reductions in TB transmission through a combination of earlier case 277 identification and reduction in loss-to-follow-up from the point of diagnosis to the initiation of 278 treatment. A POC diagnostic test could significantly reduce initial loss-to-follow-up in the care cascade. 279
Analyses of country-level data in South Africa have shown losses of approximately 12% between 280 diagnosis and treatment initiation, which could potentially be diminished by POC testing [56] [57] [58] . 281
Importantly, the ability to reduce these losses will also depend on other aspects of the overall care 282 cascade such as the ability to perform drug susceptibility testing in LAM-positive patients. Modelling of 283
intensified case-finding among HIV clinic attendees in South Africa has suggested reductions in mortality 284 of up to 30% over 10 years if LAM test sensitivity is near the biomarker TPP of 65% [59] . Analyses of the 285 potential impact of introducing LAM into the diagnostic and care cascades will need to view LAM testing 286 in the context of its placement in specific health care systems and its relationship to other available 287 diagnostics. 288 289
Conclusion 290 Urine LAM is a promising TB diagnostic biomarker for use in a POC TB test, with the potential to reach 291 adult and pediatric patients regardless of HIV status or site of infection. The ultimate goal of a urine LAM 292 test is to achieve sensitivity high enough to reach and benefit all TB patients while remaining specific, 293 fast, simple, and affordable to use. FujiLAM offers greater sensitivity than AlereLAM and is therefore 294 likely to extend the indication of TB LAM testing beyond seriously ill HIV-positive patients. However, 295
several research questions remain to be addressed ( Table 2) . With dedicated research driving the next 296 generation of urine LAM diagnostics for clinic-based TB detection, there is a clear path forward to making 297 a significant public health impact and facilitating global TB control. Implementation and scale-up of 298 existing LAM tests and development of next-generation assays should be prioritized. 299 Can sensitive, specific, low-cost, simple, and rapid platform alternatives be developed that substantially improve POC detection compared to conventional lateral-flow assays? 3
Which of the currently available antibodies yield the best performance in immunoassays? 4
What simple and POC-amenable specimen processing steps would improve the availability for detection or increase the concentration of LAM in clinical samples? 5
Are multiple molecular species of LAM present in clinical specimens, implying the need for polyclonal antibodies or multiple sets of monoclonal antibodies? 6
What purified LAM antigen preparations best mimic what is found in patient samples? 7
What is the molecular structure of LAM released from M. tuberculosis in-vivo?
Implementation and public health impact questions

Patient-related questions 8
What is the target population and distribution? Which populations will benefit from this tool? Which populations could eventually benefit? 9
How much more impact will a next-gen test have on mortality risk reduction? 10
Can LAM tests be used to monitor treatment adherence and/or completion? 11
What are the diagnostic yields of LAM tests alone and in combination with smear microscopy or Xpert?
Operational and health systems questions 13
What is the intended level of healthcare facility and user level of training required? 14
How much time is saved by using this tool versus other standard of care tools?
Policy and access questions 15
What global institutions, technical experts, and financing organizations are considered key influencers in the global market for this product? And how are we engaging with them? 16
What are the early-adopter countries that may drive product uptake and expansion? Which countries are potential new markets for next-gen LAM tests? 17
How will next-gen LAM tests integrate into current WHO guidelines and TPPs for TB detection? In inpatient settings, WHO strongly recommends using LF-LAM to assist in the diagnosis of active TB in HIV-positive adults, adolescents and children:
• with signs and symptoms of TB (pulmonary and/or extrapulmonary) (strong recommendation; moderate certainty in the evidence about the intervention effects); or • with advanced HIV disease or who are seriously ill (strong recommendation; moderate certainty in the evidence about the intervention effects); or • irrespective of signs and symptoms of TB and with a CD4 count <200 cells/mm 3 (strong recommendation; moderate certainty in the evidence about the intervention effects).
In outpatient settings, WHO suggests using LF-LAM to assist in the diagnosis of active TB in HIVpositive adults, adolescents and children:
• with signs and symptoms of TB (pulmonary and/or extrapulmonary) or "seriously ill" (conditional recommendation; low certainty in the evidence about test accuracy); and • irrespective of signs and symptoms of TB and with a CD4 count of less than 100 cells/mm 3 (conditional recommendation; very low certainty in the evidence about test accuracy).
In outpatient settings, WHO recommends against using LF-LAM to assist in the diagnosis of active TB in HIV-positive adults, adolescents and children:
• without assessing TB symptoms (strong; very low certainty in the evidence about test accuracy); and • without TB symptoms and unknown CD4 cell count or without TB symptoms and CD4 count ≥200 cells/mm 3 (strong; very low certainty in the evidence about test accuracy); and • without TB symptoms and with a CD4 count of 100-200 cells/mm 3 (conditional; very low certainty in the evidence about test accuracy).
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